Ionis Pharmaceuticals (NASDAQ: IONS) CEO receives 85,410 options

Rhea-AI Filing Summary

Ionis Pharmaceuticals reported an equity award for its Chief Executive Officer, Brett P. Monia. On 01/02/2026, he received a grant of 85,410 non-qualified stock options under the company’s Amended and Restated 2011 Equity Incentive Plan, with an exercise price of $79.67 per share.

According to the vesting terms, the option was not exercisable on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, and the remaining shares will vest in 36 equal monthly installments over the following three years, ending before the option’s 01/01/2036 expiration date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Monia Brett P

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	85,410	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 85,410 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$79.67	01/02/2026		A		85,410		01/02/2027(1)	01/01/2036	Common Stock	85,410	$0.0	85,410	D

Explanation of Responses:

1. Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ionis Pharmaceuticals (IONS) disclose in this Form 4?

The filing discloses that Chief Executive Officer Brett P. Monia received a grant of 85,410 non-qualified stock options to purchase Ionis Pharmaceuticals common stock.

How many stock options were granted to Ionis CEO Brett Monia and at what price?

Brett Monia was granted 85,410 non-qualified stock options, each with an exercise price of $79.67 per share.

When do the newly granted Ionis stock options start vesting?

The options were not exercisable on 01/02/2026. 25% of the shares will vest and become exercisable on 01/02/2027.

What is the vesting schedule for the remaining Ionis stock options granted to the CEO?

After the initial 25% vests on 01/02/2027, the remaining shares will vest and become exercisable in 36 equal monthly installments over the next three years.

What is the expiration date of the stock options granted to the Ionis CEO?

The non-qualified stock options granted on 01/02/2026 are scheduled to expire on 01/01/2036, if not exercised earlier and subject to the plan’s terms.

Are the stock options held directly or indirectly by the Ionis CEO?

The Form 4 indicates the 85,410 stock options are held with direct ownership by the reporting person.